Abstract
Activation of immune-inflammatory and oxidative-nitrosative (IO&NS) stress pathways plays a role in major depression (MDD). Evidence suggests that curcumin (500–1000 mg/day), a polyphenol with strong anti-IO&NS properties, may have efficacy either as monotherapy or as an adjunctive treatment for depression. Further controlled trials with extended treatment periods (> 8 weeks) and higher curcumin doses are warranted. This 12-week study was carried out to examine the effects of adjunctive curcumin for the treatment of MDD. In this double-blind, placebo-controlled trial, 65 participants with MDD were randomized to receive either adjunctive curcumin (increasing dose from 500 to 1500 mg/day) or placebo for 12 weeks. Four weeks after the active treatment phase, a follow-up visit was conducted at week 16. Assessments of the primary, i.e., the Montgomery-Asberg Depression Rating Scale (MADRS), and secondary, i.e., the Hamilton Anxiety Rating Scale (HAM-A), outcome measures were rated at baseline and 2, 4, 8, 12, and 16 weeks later. Curcumin was more efficacious than placebo in improving MADRS scores with significant differences between curcumin and placebo emerging at weeks 12 and 16. The effects of curcumin were more pronounced in males compared to females. There were no statistically significant treatment-emerging adverse effects and no significant effects of curcumin on blood chemistry and ECG measurements. Adjunctive curcumin has significant antidepressant effects in participants with MDD as evidenced by significant benefits occurring 12 and 16 weeks after treatment initiation. Curcumin administration was safe and well-tolerated even when combined with antidepressants. Future trials should include treatment-by-sex interactions to examine putative antidepressant effects of immune-modifying compounds.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Al-Karawi D, Al Mamoori DA, Tayyar Y (2016) The role of curcumin administration in patients with major depressive disorder: Mini meta-analysis of clinical trials. Phytother Res 30(2):175–183. https://doi.org/10.1002/ptr.5524
Anderson G, Maes M (2014) TRYCAT pathways link peripheral inflammation, nicotine, somatization and depression in the etiology and course of Parkinson's disease. CNS Neurol Disord Drug Targets 13(1):137–149. https://doi.org/10.2174/18715273113129990082
Banji D, Banji OJ, Dasaroju S, Kranthi KC (2013) Curcumin and piperine abrogate lipid and protein oxidation induced by D-galactose in rat brain. Brain Res 1515:1–11. https://doi.org/10.1016/j.brainres.2013.03.023
Bassler D, Briel M, Montori VM, Lane M, Glasziou P, Zhou Q, Heels-Ansdell D, Walter SD, Guyatt GH, STOPIT-2 Study Group, Flynn DN, Elamin MB, Murad MH, Abu Elnour NO, Lampropulos JF, Sood A, Mullan RJ, Erwin PJ, Bankhead CR, Perera R, Ruiz Culebro C, You JJ, Mulla SM, Kaur J, Nerenberg KA, Schünemann H, Cook DJ, Lutz K, Ribic CM, Vale N, Malaga G, Akl EA, Ferreira-Gonzalez I, Alonso-Coello P, Urrutia G, Kunz R, Bucher HC, Nordmann AJ, Raatz H, da Silva SA, Tuche F, Strahm B, Djulbegovic B, Adhikari NK, Mills EJ, Gwadry-Sridhar F, Kirpalani H, Soares HP, Karanicolas PJ, Burns KE, Vandvik PO, Coto-Yglesias F, Chrispim PP, Ramsay T (2010) Stopping randomized trials early for benefit and estimation of treatment effects: systematic review and meta-regression analysis. JAMA 303(12):1180–1187. https://doi.org/10.1001/jama.2010.310
Bilici M, Efe H, Köroğlu MA, Uydu HA, Bekaroğlu M, Değer O (2001) Antioxidative enzyme activities and lipid peroxidation in major depression: alterations by antidepressant treatments. J Affect Disord 64(1):43–51. https://doi.org/10.1016/S0165-0327(00)00199-3
Bortolasci CC, Vargas HO, Souza-Nogueira A, Barbosa DS, Moreira EG, Nunes SO, Berk M, Dodd S, Maes M (2014) Lowered plasma paraoxonase (PON)1 activity is a trait marker of major depression and PON1 Q192R gene polymorphism-smoking interactions differentially predict the odds of major depression and bipolar disorder. J Affect Disord 159:23–30. https://doi.org/10.1016/j.jad.2014.02.018
Carvalho AF, Berk M, Hyphantis TN, McIntyre RS (2014) The integrative management of treatment-resistant depression: a comprehensive review and perspectives. Psychother Psychosom 83(2):70–88. https://doi.org/10.1159/000357500
Ciftci G, Aksoy A, Cenesiz S, Sogut MU, Yarim GF, Nisbet C, Guvenc D, Ertekin A (2015) Therapeutic role of curcumin in oxidative DNA damage caused by formaldehyde. Microsc Res Tech 78(5):391–395. https://doi.org/10.1002/jemt.22485
de Melo LGP, Nunes SOV, Anderson G, Vargas HO, Barbosa DS, Galecki P, Carvalho AF, Maes M (2017) Shared metabolic and immune-inflammatory, oxidative and nitrosative stress pathways in the metabolic syndrome and mood disorders. Prog Neuro-Psychopharmacol Biol Psychiatry 78:34–50. https://doi.org/10.1016/j.pnpbp.2017.04.027
de Oliveira MR, Jardim FR, Setzer WN, Nabavi SM, Nabavi SF (2016) Curcumin, mitochondrial biogenesis, and mitophagy: exploring recent data and indicating future needs. Biotechnol Adv 34(5):813–826. https://doi.org/10.1016/j.biotechadv.2016.04.004
Esmaily H, Sahebkar A, Iranshahi M, Ganjali S, Mohammadi A, Ferns G, Ghayour-Mobarhan M (2015) An investigation of the effects of curcumin on anxiety and depression in obese individuals: a randomized controlled trial. Chin J Integr Med 21(5):332–338. https://doi.org/10.1007/s11655-015-2160-z
Farooqui AA (2016) Therapeutic potentials of curcumin for Alzheimer disease. Springer, Berlin. https://doi.org/10.1007/978-3-319-15889-1
Gałecki P, Gałecka E, Maes M, Chamielec M, Orzechowska A, Bobińska K, Lewiński A, Szemraj J (2012) The expression of genes encoding for COX-2, MPO, iNOS, and sPLA2-IIA in patients with recurrent depressive disorder. J Affect Disord 138(3):360–366. https://doi.org/10.1016/j.jad.2012.01.016
Ganjali S, Blesso CN, Banach M, Pirro M, Majeed M, Sahebkar A (2017) Effects of curcumin on HDL functionality. Pharmacol Res 119:208–218. https://doi.org/10.1016/j.phrs.2017.02.008
Ghandadi M, Sahebkar A (2017) Curcumin: an effective inhibitor of interleukin-6. Curr Pharm Des 23(6):921–931. https://doi.org/10.2174/1381612822666161006151605
Gomes C, Martinho FC, Barbosa DS, Antunes LS, Póvoa HCC, Baltus THL, Morelli NR, Vargas HO, Nunes SOV, Anderson G, Maes M (2017) Increased root canal endotoxin levels are associated with chronic apical periodontitis, increased oxidative and nitrosative stress, major depression, severity of depression, and a lowered quality of life. Mol Neurobiol. https://doi.org/10.1007/s12035-017-0545-z
González-Reyes S, Guzmán-Beltrán S, Medina-Campos ON, Pedraza-Chaverri J (2013) Curcumin pretreatment induces Nrf2 and an antioxidant response and prevents hemin-induced toxicity in primary cultures of cerebellar granule neurons of rats. Oxidative Med Cell 2013:801418
Hamilton M (1959) The assessment of anxiety states by rating. Br J Med Psychol 32(1):50–55. https://doi.org/10.1111/j.2044-8341.1959.tb00467.x
Hewlings SJ, Kalman DS (2017) Curcumin: a review of Its’ effects on human health. Foods 6(10). https://doi.org/10.3390/foods6100092
Howren MB, Lamkin DM, Suls J (2009) Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med 71(2):171–186. https://doi.org/10.1097/PSY.0b013e3181907c1b
Jeong YI, Kim SW, Jung ID, Lee JS, Chang JH, Lee CM, Chun SH, Yoon MS, Kim GT, Ryu SW, Kim JS, Shin YK, Lee WS, Shin HK, Lee JD, Park YM (2009) Curcumin suppresses the induction of indoleamine 2,3-dioxygenase by blocking the Janus-activated kinase-protein kinase Cdelta-STAT1 signaling pathway in interferon-gamma-stimulated murine dendritic cells. J Biol Chem 284(6):3700–3708. https://doi.org/10.1074/jbc.M807328200
Jurrmann N, Brigelius-Flohé R, Böl GF (2005) Curcumin blocks interleukin-1 (IL-1) signaling by inhibiting the recruitment of the IL-1 receptor-associated kinase IRAK in murine thymoma EL-4 cells. J Nutr 135(8):1859–1864
Kaufmann FN, Gazal M, Bastos CR, Kaster MP, Ghisleni G (2016) Curcumin in depressive disorders: an overview of potential mechanisms, preclinical and clinical findings. Eur J Pharmacol 784:192–198. https://doi.org/10.1016/j.ejphar.2016.05.026
Kittirathanapaiboon P, Khamwongpin M (2005) The validity of the Mini International Neuropsychiatric Interview (M.I.N.I.) Thai version. Suanprung Hospital, Department of Mental Health
Köhler O, Benros ME, Nordentoft M, Farkouh ME, Iyengar RL, Mors O, Krogh J (2014) Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects: a systematic review and meta-analysis of randomized clinical trials. JAMA Psychiatry 71(12):1381–1391. https://doi.org/10.1001/jamapsychiatry.2014.1611
Köhler CA, Freitas TH, Maes M, de Andrade NQ, Liu CS, Fernandes BS, Stubbs B, Solmi M, Veronese N, Herrmann N, Raison CL, Miller BJ, Lanctôt KL, Carvalho AF (2017a) Peripheral cytokine and chemokine alterations in depression: a meta-analysis of 82 studies. Acta Psychiatr Scand 135(5):373–387. https://doi.org/10.1111/acps.12698
Köhler CA, Freitas TH, Stubbs B, Maes M, Solmi M, Veronese N, de Andrade NQ, Morris G, Fernandes BS, Brunoni AR, Herrmann N, Raison CL, Miller BJ, Lanctôt KL, Carvalho AF (2017b) Peripheral alterations in cytokine and chemokine levels after antidepressant drug treatment for major depressive disorder: systematic review and meta-analysis. Mol Neurobiol. https://doi.org/10.1007/s12035-017-0632-1
Leonard B, Maes M (2012) Mechanistic explanations how cell-mediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants play a role in the pathophysiology of unipolar depression. Neurosci Biobehav Rev 36(2):764–785. https://doi.org/10.1016/j.neubiorev.2011.12.005
Liu Y, Ho RC, Mak A (2012) Interleukin (IL)-6, tumour necrosis factor alpha (TNF-α) and soluble interleukin-2 receptors (sIL-2R) are elevated in patients with major depressive disorder: a meta-analysis and meta-regression. J Affect Disord 139(3):230–239. https://doi.org/10.1016/j.jad.2011.08.003
Liu T, Zhong S, Liao X, Chen J, He T, Lai S, Jia Y (2015) A meta-analysis of oxidative stress markers in depression. PLoS One 10(10):e0138904. https://doi.org/10.1371/journal.pone.0138904
Lopresti AL (2017) Curcumin for neuropsychiatric disorders: a review of in vitro, animal and human studies. J Psychopharmacol 31(3):287–302. https://doi.org/10.1177/0269881116686883
Lopresti AL, Drummond PD (2017) Efficacy of curcumin, and a saffron/curcumin combination for the treatment of major depression: a randomised, double-blind, placebo-controlled study. J Affect Disord 207:188–196. https://doi.org/10.1016/j.jad.2016.09.047
Lopresti AL, Hood SD, Drummond PD (2012) Multiple antidepressant potential modes of action of curcumin: a review of its anti-inflammatory, monoaminergic, antioxidant, immune-modulating and neuroprotective effects. J Psychopharmacol 26(12):1512–1524. https://doi.org/10.1177/0269881112458732
Lopresti AL, Maes M, Maker GL, Hood SD, Drummond PD (2014) Curcumin for the treatment of major depression: a randomised, double-blind, placebo controlled study. J Affect Disord 167:368–375. https://doi.org/10.1016/j.jad.2014.06.001
Lopresti AL, Maes M, Meddens MJ, Maker GL, Arnoldussen E, Drummond PD (2015) Curcumin and major depression: a randomised, double-blind, placebo-controlled trial investigating the potential of peripheral biomarkers to predict treatment response and antidepressant mechanisms of change. Eur Neuropsychopharmacol 25(1):38–50. https://doi.org/10.1016/j.euroneuro.2014.11.015
Maes M (1995) Evidence for an immune response in major depression: a review and hypothesis. Prog Neuro-Psychopharmacol Biol Psychiatry 19(1):11–38. https://doi.org/10.1016/0278-5846(94)00101-M
Maes M (2005) Van Freud tot omega-3, 2005. Standaard Uitgeverij, Antwerpen, 240 pagina's, 9789002214813
Maes M (2008) The cytokine hypothesis of depression: inflammation, oxidative & nitrosative stress (IO&NS) and leaky gut as new targets for adjunctive treatments in depression. Neuro Endocrinol Lett 29(3):287–291
Maes M, Bosmans E, Suy E, Vandervorst C, De Jonckheere C, Raus J (1990) Immune disturbances during major depression: upregulated expression of interleukin-2 receptors. Neuropsychobiology 24(3):115–120. https://doi.org/10.1159/000119472
Maes M, Delanghe J, Meltzer HY, Scharpé S, D'Hondt P, Cosyns P (1994) Lower degree of esterification of serum cholesterol in depression: relevance for depression and suicide research. Acta Psychiatr Scand 90(4):252–258. https://doi.org/10.1111/j.1600-0447.1994.tb01589.x
Maes M, Smith R, Christophe A, Vandoolaeghe E, Van Gastel A, Neels H, Demedts P, Wauters A, Meltzer HY (1997) Lower serum high-density lipoprotein cholesterol (HDL-C) in major depression and in depressed men with serious suicidal attempts: relationship with immune-inflammatory markers. Acta Psychiatr Scand 95(3):212–221
Maes M, Christophe A, Delanghe J, Altamura C, Neels H, Meltzer HY (1999) Lowered omega3 polyunsaturated fatty acids in serum phospholipids and cholesteryl esters of depressed patients. Psychiatry Res 85(3):275–291. https://doi.org/10.1016/S0165-1781(99)00014-1
Maes M, De Vos N, Pioli R, Demedts P, Wauters A, Neels H, Christophe A (2000) Lower serum vitamin E concentrations in major depression. Another marker of lowered antioxidant defenses in that illness. J Affect Disord 58(3):241–246. https://doi.org/10.1016/S0165-0327(99)00121-4
Maes M, Yirmyia R, Noraberg J, Brene S, Hibbeln J, Perini G, Kubera M, Bob P, Lerer B, Maj M (2009) The inflammatory & neurodegenerative (I&ND) hypothesis of depression: leads for future research and new drug developments in depression. Metab Brain Dis 24(1):27–53. https://doi.org/10.1007/s11011-008-9118-1
Maes M, Galecki P, Chang YS, Berk M (2011a) A review on the oxidative and nitrosative stress (O&NS) pathways in major depression and their possible contribution to the (neuro)degenerative processes in that illness. Prog Neuro-Psychopharmacol Biol Psychiatry 35(3):676–692. https://doi.org/10.1016/j.pnpbp.2010.05.004
Maes M, Leonard BE, Myint AM, Kubera M, Verkerk R (2011b) The new '5-HT' hypothesis of depression: cell-mediated immune activation induces indoleamine 2,3-dioxygenase, which leads to lower plasma tryptophan and an increased synthesis of detrimental tryptophan catabolites (TRYCATs), both of which contribute to the onset of depression. Prog Neuro-Psychopharmacol Biol Psychiatry 35(3):702–721
Maes M, Mihaylova I, Kubera M, Leunis JC, Geffard M (2011c) IgM-mediated autoimmune responses directed against multiple neoepitopes in depression: new pathways that underpin the inflammatory and neuroprogressive pathophysiology. J Affect Disord 135(1–3):414–418. https://doi.org/10.1016/j.jad.2011.08.023
Maes M, Fišar Z, Medina M, Scapagnini G, Nowak G, Berk M (2012) New drug targets in depression: inflammatory, cell-mediated immune, oxidative and nitrosative stress, mitochondrial, antioxidant, and neuroprogressive pathways. And new drug candidates--Nrf2 activators and GSK-3 inhibitors. Inflammopharmacology 20(3):127–150. https://doi.org/10.1007/s10787-011-0111-7
Montgomery SA, Asberg M (1979) A new depression scale designed to be sensitive to change. Brit J Psychiatry 134(4):382–389. https://doi.org/10.1192/bjp.134.4.382
Moylan S, Maes M, Wray NR, Berk M (2013) The neuroprogressive nature of major depressive disorder: pathways to disease evolution and resistance, and therapeutic implications. Mol Psychiatry 18(5):595–606. https://doi.org/10.1038/mp.2012.33
Ng QX, Koh SSH, Chan HW, Ho CYX (2017) Clinical use of curcumin in depression: a meta-analysis. J Am Med Dir Assoc 18(6):503–508. https://doi.org/10.1016/j.jamda.2016.12.071
Panahi Y, Badeli R, Karami GR, Sahebkar A (2015) Investigation of the efficacy of adjunctive therapy with bioavailability-boosted curcuminoids in major depressive disorder. Phytother Res 29(1):17–21. https://doi.org/10.1002/ptr.5211
Peet M, Murphy B, Shay J, Horrobin D (1998) Depletion of omega-3 fatty acid levels in red blood cell membranes of depressive patients. Biol Psychiatry 43(5):315–319. https://doi.org/10.1016/S0006-3223(97)00206-0
Psaty BM, Rennie D (2003) Stopping medical research to save money: a broken pact with researchers and patients. JAMA 289(16):2128–2131. https://doi.org/10.1001/jama.289.16.2128
Rizavi HS, Ren X, Zhang H, Bhaumik R, Pandey GN (2016) Abnormal gene expression of proinflammatory cytokines and their membrane-bound receptors in the lymphocytes of depressed patients. Psychiatry Res 240:314–320. https://doi.org/10.1016/j.psychres.2016.04.049
Roomruangwong C, Barbosa DS, Matsumoto AK, Nogueira AS, Kanchanatawan B, Sirivichayakul S, Carvalho AF, Duleu S, Geffard M, Moreira EG, Maes M (2017) Activated neuro-oxidative and neuro-nitrosative pathways at the end of term are associated with inflammation and physio-somatic and depression symptoms, while predicting outcome characteristics in mother and baby. J Affect Disord 223:49–58. https://doi.org/10.1016/j.jad.2017.07.002
Sanmukhani J, Satodia V, Trivedi J, Patel T, Tiwari D, Panchal B, Goel A, Tripathi CB (2014) Efficacy and safety of curcumin in major depressive disorder: a randomized controlled trial. Phytother Res 28(4):579–585. https://doi.org/10.1002/ptr.5025
Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E et al (1998) The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 59(Suppl 20):22–23
Slyepchenko A, Maes M, Köhler CA, Anderson G, Quevedo J, Alves GS, Berk M, Fernandes BS, Carvalho AF (2016) T helper 17 cells may drive neuroprogression in major depressive disorder: proposal of an integrative model. Neurosci Biobehav Rev 64:83–100. https://doi.org/10.1016/j.neubiorev.2016.02.002
Sobczak S, Honig A, Christophe A, Maes M, Helsdingen RW, De Vriese SA, Riedel WJ (2004) Lower high-density lipoprotein cholesterol and increased omega-6 polyunsaturated fatty acids in first-degree relatives of bipolar patients. Psychol Med 34(1):103–112. https://doi.org/10.1017/S0033291703001090
Soto-Urquieta MG, López-Briones S, Pérez-Vázquez V, Saavedra-Molina A, González-Hernández GA, Ramírez-Emiliano J (2014) Curcumin restores mitochondrial functions and decreases lipid peroxidation in liver and kidneys of diabetic db/db mice. Biol Res 47(1):74. https://doi.org/10.1186/0717-6287-47-74
Tsuboi H, Tatsumi A, Yamamoto K, Kobayashi F, Shimoi K, Kinae N (2006) Possible connections among job stress, depressive symptoms, lipid modulation and antioxidants. J Affect Disord 91(1):63–70. https://doi.org/10.1016/j.jad.2005.12.010
Valkanova V, Ebmeier KP, Allan CL (2013) CRP, IL-6 and depression: a systematic review and meta-analysis of longitudinal studies. J Affect Disord 150(3):736–744. https://doi.org/10.1016/j.jad.2013.06.004
Vargas HO, Nunes SO, Pizzo de Castro M, Bortolasci CC, Sabbatini Barbosa D, Kaminami Morimoto H, Venugopal K, Dodd S, Maes M, Berk M (2013) Oxidative stress and lowered total antioxidant status are associated with a history of suicide attempts. J Affect Disord 150(3):923–930. https://doi.org/10.1016/j.jad.2013.05.016
Yu JJ, Pei LB, Zhang Y, Wen ZY, Yang JL (2015) Chronic supplementation of curcumin enhances the efficacy of antidepressants in major depressive disorder: a randomized, double-blind, placebo-controlled pilot study. J Clin Psychopharmacol 35(4):406–410
Acknowledgements
This research has been supported by the Agricultural Research Developmental Agency (ARDA), Bangkok, Thailand. The funding agency played no role in dada reporting. The authors would like to thank Supaksorn Thika (ST) for her valuable help completing the rating scales.
Author information
Authors and Affiliations
Contributions
All the contributing authors have participated in the manuscript. BK and MM designed the study. BK recruited patients and completed diagnostic interviews. All authors contributed to interpretation of the data and writing of the manuscript. MM carried out the statistical analyses.
Corresponding author
Ethics declarations
Conflict of Interest
The authors have no conflict of interest with any commercial or other association in connection with the submitted article.
Rights and permissions
About this article
Cite this article
Kanchanatawan, B., Tangwongchai, S., Sughondhabhirom, A. et al. Add-on Treatment with Curcumin Has Antidepressive Effects in Thai Patients with Major Depression: Results of a Randomized Double-Blind Placebo-Controlled Study. Neurotox Res 33, 621–633 (2018). https://doi.org/10.1007/s12640-017-9860-4
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12640-017-9860-4